1. Holmfred A, Vikerfors T, Berggren L, Gupta A. Intrathecal catheters with subcutaneous port systems in patients with severe cancer-related pain managed out of hospital: the risk of infection. J Pain Symptom Manage. 2006; 31:568–572. PMID:
16793497.
Article
2. Vissers KC, Besse K, Wagemans M, Zuurmond W, Giezeman MJ, Lataster A, et al. 23. Pain in patients with cancer. Pain Pract. 2011; 11:453–475. PMID:
21679293.
3. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20:4040–4049. PMID:
12351602.
Article
4. Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011; 14:E283–E312. PMID:
21587338.
5. Hong SH, Lee GW. Upper body cancer pain management by cervical intrathecal catheterization: a case report. Korean J Anesthesiol. 2008; 55:135–138.
Article
6. Seo KC, Chung JY, Kim HY, Rho WS, Kim BI, Song SY. Intrathecal catheter and subcutaneous access port implantation in pain management for terminal cancer patient: a case report. Korean J Pain. 2007; 20:240–245.
Article
7. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011; 25:504–515. PMID:
21708857.
Article
8. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003; 4:441–447. PMID:
14622664.
Article
9. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg. 2000; 75:16–26. PMID:
11416261.
Article
10. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104:570–587. PMID:
16508405.
Article
11. Krames ES. Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manage. 1993; 8:36–46. PMID:
8482892.
Article
12. Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics. 2008; 5:114–122. PMID:
18164490.
Article
13. Aldrete JA. Intrathecal opioid infusions. Anesthesiology. 2004; 101:256. author reply 257-8. PMID:
15220803.
Article
14. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999; 44:289–300. discussion 300-1. PMID:
9932882.
Article
15. Bailey PL, Rhondeau S, Schafer PG, Lu JK, Timmins BS, Foster W, et al. Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology. 1993; 79:49–59. discussion 25A. PMID:
8342828.
Article
16. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996; 85:458–467. PMID:
8751633.
Article
17. Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993; 33:226–230. discussion 230. PMID:
7690122.
Article